- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06338436
Varian ProBeam Proton Therapy System China Clinical Trial (Guangzhou)
This study is prospective, single-center, single-arm objective performance criteria.
This trial will be conducted with a total of 47 subjects enrolled. All of subjects will be treated with radiation therapy using the medical device Varian ProBeam Proton Therapy System (ProBeam), aim to compare the data with objective performance criteria (OPC) to evaluate the effectiveness and safety of ProBeam radiotherapy system for oncology patients, providing a clinical basis for the medical device registration.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Oncology patients, including tumors of head and neck, chest, abdomen, spine, pelvic cavity, extremities and other tumors. The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan. The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion. The clinical trial with short-term follow-up fulfills the requirements for National Medical Products Administration (NMPA) regulatory registration. All the end points claimed will be achieved in the short-term follow-up stage. The trial is defined as completion once short-term follow-up is finished.
And long-term follow-up report will be submitted for future post market evaluation when requested by NMPA.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Guangdong
-
Guangzhou, Guangdong, China
- Sun Yat-sen Memorial Hospital, Sun Yat-sen University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria (Major Criteria):
- Confirmed by cellular or histopathological diagnosis and/or evidence of imaging or laboratory tests, with a clinical diagnosis of benign, Patients with malignant intracranial tumors, as well as malignant solid tumors of the head and neck, chest, abdomen, spine, pelvis, and extremity;
- The target lesion is a measurable solid tumor, and the longest diameter of the lesion should be ≥10mm;
- Those who have an expected survival time of more than 6 months;
- Eastern Cooperative Oncology Group (ECOG) physical status is graded as 0~2;
- Females of childbearing potential with a negative blood or urine pregnancy test result within 7 days prior to the first treatment;
Exclusion Criteria (Major Criteria):
- There are contraindications to radiation therapy, including congenital susceptibility to ionizing radiation hypersensitivity; or the presence of comorbidity that may lead to ionizing radiation hypersensitivity, which will increase the sensitivity of normal tissues to radiation therapy;
- The tumor recurring at the same site has received two or more radiotherapy treatments;
- Active implants such as cardiac pacemakers, defibrillators, cochlear implants, drug infusion pumps, other nerve stimulators, etc. (whether they are turned on or not) within the scope of radiotherapy ; or passive implants that affect radiotherapy thing;
- Other situations that investigator determines not suitable for enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: single-arm objective performance criteria (OPC)
According to the National Medical Products Administration (NMPA) Guidance on Proton and Carbon Ion treatment system clinical evaluation and clinical trial, the objective performance criteria for the validity of medical device treatment for trial use should be at least 80%, with an expected target of 95% in which the validity is defined as: Complete Response (CR) + Partial Response (PR)+ Stable Disease (SD), and the definition of tumor disease control rate in this clinical trial is basically identical.
Therefore, the clinical trial did not have a control group, but using single-arm objective performance criteria, when evaluating ProBeam radiotherapy for tumor patients, the main validity evaluation index of tumor disease control rate; the main safety evaluation by incident of acute radiation injury and adverse event.
|
All enrolled subjects will be treated with Proton radiation therapy using the medical device Varian Proton Therapy System (ProBeam).
The screening period from informed consent to enrollment is expected to be 2 weeks, while the treatment period depends on patient medical situation and treatment plan.
The period after the last treatment is divided into short-term follow-up which is 90 days after treatment completion and long-term follow-up which is 5 years after treatment completion.
The clinical trial with short-term follow-up fulfills the requirements for NMPA regulatory registration.
All the end points claimed will be achieved in the short-term follow-up stage.
The trial is defined as completion once short-term follow-up is finished.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness evaluation: Local tumor control rate 90 days after the proton radiation treatment completion
Time Frame: 90 days ± 7 days after treatment completion
|
At 90 days after the treatment completion, the number of cases in partial response (PR) and stable disease (SD) and complete response (CR) accounted for the proportion of total cases will be rated according to Response Evaluation Criteria in Solid Tumors RECIST Version 1.1 (RECIST 1.1) criteria.
|
90 days ± 7 days after treatment completion
|
Safety evaluation: Incidence of Acute radiation injury
Time Frame: from enrollment to 90 days ± 7 days after treatment completion
|
Observe acute radiation injury occurrence throughout the trial period, including the treatment period and the 90-day follow-up period.
Acute radiation injury will be summarized separately (calculating quantity of participants, number of cases, and incidence) based on Radiation Therapy Oncology Group (RTOG) Grading Criteria.
|
from enrollment to 90 days ± 7 days after treatment completion
|
Safety evaluation: Incidence of Adverse Events based on CTCAE 5.0 criteria
Time Frame: from enrollment to 90 days ± 7 days after treatment completion
|
Record Incidence of Adverse Events and estimate according to Common Terminology Criteria for Adverse Events version 5.0 (CTCAE 5.0) criteria, level 3 toxic reaction ratio should be lower than the acceptable value (5%), level 4 and 5 toxic reaction should not occur.
|
from enrollment to 90 days ± 7 days after treatment completion
|
Collaborators and Investigators
Investigators
- Principal Investigator: Yimin Liu, Sun Yat-sen Memorial Hospital,Sun Yat-sen University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- VAR-2022-05
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Tumor, Solid
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on Proton Radiation Therapy System (ProBeam)
-
Varian, a Siemens Healthineers CompanyCompleted
-
Varian, a Siemens Healthineers CompanyCompleted
-
P-CureHadassah Medical OrganizationRecruitingBrain Cancer | Thoracic Cancer | Head Cancer | Neck Cancer | Pancreatic Cancer Non-resectableIsrael
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8United States
-
Proton Collaborative GroupActive, not recruitingProstate CancerUnited States
-
Varian, a Siemens Healthineers CompanyNot yet recruiting
-
Loma Linda UniversityCompleted
-
Guangzhou Concord Cancer CenterSun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Varian, a Siemens...CompletedSolid Tumor | Proton Therapy | Radiation TherapyChina
-
Massachusetts General HospitalNational Cancer Institute (NCI)CompletedLow Grade GliomasUnited States
-
Emory UniversityNational Cancer Institute (NCI)Not yet recruitingResectable Lung Non-Small Cell CarcinomaUnited States